Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

Overview

The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.

Full Title of Study: “An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2005

Detailed Description

The purpose of this study is to evaluate the analgesic effectiveness and tolerability of oxymorphone ER in the treatment of cancer or neuropathic pain. Opioid-naïve subjects are gradually titrated from oxymorphone ER 5 mg, every 12 hours (q12h). All other subjects are titrated to a stable dose (defined as pain scores ≥ 4 on BPI Question 5 on 3 of 5 consecutive days while receiving the same total daily dose of study medication including rescue) with tolerable side effects. Subjects could potentially receive therapy for up to 12 months after the first dose of study medication.

Interventions

  • Drug: Oxymorphone Extended Release
    • Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets Treatment will consist of up to 12 months of dosing with Oxymorphone ER.

Arms, Groups and Cohorts

  • Experimental: Single Arm

Clinical Trial Outcome Measures

Primary Measures

  • Tolerability
    • Time Frame: Throughout the study

Secondary Measures

  • Average daily pain intensity (Question 5 of BPI)
    • Time Frame: Week 1-4, Month 12
  • Question 3, 4, 5, 6, 8, and 9 of BPI questionnaire
    • Time Frame: Week 1-4, Month 12
  • Average daily dose of oxymorphone ER
    • Time Frame: Daily
  • Average daily dose of rescue medication
    • Time Frame: Daily
  • Total daily dose of oxymorphone ER and rescue medication
    • Time Frame: Daily
  • Time to stabilization
    • Time Frame: Month 12
  • Patient/investigator global assessment of pain relief
    • Time Frame: Month 12
  • Treatment Satisfaction
    • Time Frame: Month 12

Participating in This Clinical Trial

Inclusion Criteria

  • ≥ 18 years of age or older, with moderate to severe chronic malignant and/or neuropathic pain of at least 3 months duration and either: 1. have an initial pain intensity score of greater than 4 on a 10-point scale using BPI Question 5, if sub-optimally responding to their current analgesic regimen, or 2. have intolerable side effects to one or more components of their current opioid-containing analgesic regimen. – Currently receive a stable (at least 2 weeks duration) analgesic regimen – If female, must be practicing abstinence or using a medically acceptable form of contraception (e.g., intrauterine device, hormonal birth control, or double barrier method). – Understand written and spoken English – Have been informed of the nature of the study and provided written informed consent Additional Inclusion Criteria for Cancer Patients Only: – Have a life expectancy of at least 12 months Additional Inclusion Criteria for Neuropathic Patients Only: – Have a diagnosis of: – post-herpetic neuralgia (PHN) – diabetic neuropathy (DN) – complex regional pain syndrome (CRPS) – HIV neuropathy – idiopathic sensory neuropathy – traumatic peripheral neuropathy – central neuropathic pain condition (spinal cord injury, post-stroke pain), OR – other peripheral neuropathy (upon mutual agreement of the sponsor and investigator). Exclusion Criteria:

  • Have a positive pregnancy test (females only) – Have a history of or active asthma or emphysema – Have clinically significant hepatic impairment – Have a history of alcohol or substance abuse within the last 3 years – Have a history of opioid abuse within 6 months prior to study entry – Have a known allergy or significant reaction to opioids, including codeine – Have a known oxymorphone sensitivity or allergy – Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Endo Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sr. Director, CR&D, Endo Pharmaceuticals Inc.
  • Overall Official(s)
    • Study Director, Study Director, Endo Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.